What is claimed is:
1. A steel sheet for heat shrink band, having anhysteretic magnetic permeability of 15,000 or higher at 0.35 Oe and yield stress of 24 kgfmm2 or more.
2. The steel sheet for heat shrink band of claim 1, wherein coercive force thereof is 5 Oe or less and remanent magnetic flux density is 10 kG or larger.
3. The steel sheet for heat shrink band of claim 1, containing 0.01 to 0.15%C by weight.
4. The steel sheet for heat shrink band of claim 2, containing 0.01 to 0.15% C by weight.
5. A method for manufacturing a steel sheet for heat shrink band, comprising the steps of:
hot rolling andor cold rolling a steel containing 0.01 to 0.15% C by weight;
annealing the rolled steel sheet at a temperature ranging from 650 to 900 C.; and
temper rolling the annealed steel sheet at a rolling reduction rate of 1.5% or less.
6. A method for manufacturing a steel sheet for heat shrink band, comprising the steps of:
hot rolling andor cold rolling a steel containing 0.01 to 0.15% C by weight;
annealing the rolled steel sheet at a temperature ranging from 650 to 900 C.;
overaging the annealed steel sheet at a temperature ranging from 250 to 500 C.; and
temper rolling the overaged steel sheet at a rolling reduction rate of 1.5% or less.
7. A heat shrink band made of the steel sheet of claim 1, 2, 3 or 4.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1.-11. (canceled)
12. The compound N-({(3R)-1-4-Hydroxy-4-(6-methoxy-pyridin-3-yl)-cyclohexyl-pyrrolidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide, a racemic mixture thereof, or a pharmaceutically acceptable salt thereof.
13. The compound N-({(3R)-1-4-Hydroxy-4-(6-methoxy-pyridin-3-yl)-cyclohexyl-pyrrolidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide, or a pharmaceutically acceptable salt thereof.
14. The compound N-({(3R)-1-4-Hydroxy-4-(6-methoxy-pyridin-3-yl)-cyclohexyl-pyrrolidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide.
15. A composition comprising N-({(3R)-1-4-Hydroxy-4-(6-methoxy-pyridin-3-yl)-cyclohexyl-pyrrolidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide, a racemic mixture thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
16. A method of treating multiple sclerosis in a patient comprising treating said patient with N-({(3R)-1-4-Hydroxy-4-(6-methoxy-pyridin-3-yl)-cyclohexyl-pyrrolidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide, a racemic mixture thereof, or a pharmaceutically acceptable salt thereof.
17. A method of treating nephritis in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 12, a racemic mixture thereof, or a pharmaceutically acceptable salt thereof.
18. The method of claim 17 wherein said nephritis is glomerulonephritis.